Navigation Links
Anti-fungal drug offers great benefits to some with severe asthma
Date:12/28/2008

Some patients with severe asthma who also have allergic sensitivity to certain fungi enjoy great improvements in their quality of life and on other measures after taking an antifungal drug, according to new research from The University of Manchester in England.

The findings were reported in the first issue for January of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

"We knew that many people with severe asthma are sensitized to several airborne fungi which can worsen asthma without overt clinical signs. The question was: does antifungal therapy provide any clinical benefit," said David Denning, F.R.C.P., F.R.C.Path., professor of medicine and medical mycology at The University of Manchester and lead investigator of the study.

In 2006, the most recent year for which official statistics are available, there were more than 16 million adults with self-reported asthma in the U.S.; about 20 percent of them have severe asthma.

A small number of severe asthmaticsabout one percent are known to have a syndrome called allergic bronchopulmonary aspergillosis, an extreme allergy to Aspergillus fumigatus fungus that is associated with the long-term colonization of their respiratory tracts with the fungus. But many more 20 to 50 percent are sensitized to a variety of fungi without showing overt clinical signs or demonstrable colonization. It is these patients with severe asthma with fungal sensitization, or "SAFS", as the researchers named the syndrome, who are most likely to enjoy marked improvement with the antifungal therapy.

In the prospective double-blind study, 58 patients with severe asthma and allergic sensitivity to at least one of seven different common fungi (confirmed by a skin-prick test and/or an IgE blood test for the study) were randomized to receive either an oral dose of itraconazole (200mg twice a day) or a placebo.

After 32 weeks of treatment, 18 of the 29 patients (62 percent) who were randomized to receive the drug experienced significant improvements on their Asthma Quality of Life Questionnaires, and in runny nose and morning lung function. However, 11 of the patients who received the drug left the trial before completion, some citing side effects that included nausea, breathlessness and muscle weakness. Unfortunately, four months after stopping antifungal treatment, symptoms had returned.

"This study indicates that fungal allergy is important in some patients with severe asthma, and that oral antifungal therapy is worth trying in difficult-to-treat patients. Clearly itraconazole will not suit everyone and is not always helpful, but when it is the effect is dramatic," said Dr. Denning. "These findings open the door to a new means of helping patients with severe asthma, and raise intriguing questions related to fungal allergy and asthma."

John Heffner, M.D., past president of the ATS, reflected that the recent Severe Asthma Research Program report describes severe asthma as a entirely different form of the disease. "Patients with severe asthma may have unique triggers for bronchospasm, which remain unidentified. This study suggests that colonization with fungal species may generate immunologic responses in patients with asthma that perpetuate airway inflammation and blunt the effectiveness of drug therapy. One can't help but wonder if antifungal therapy would benefit all severe asthmatics regardless of sensitivity to fungi."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Your Chemist Shop Offers Patients a Revolutionary Alternative to Other Hair Loss Treatments for Both Men and Women
2. STERIS Isomedix Services Offers Medical Device Sterilization Seminar
3. NeedyMeds.org Offers Information on Drug Discount Coupon
4. Fresho.Com Offers Efficient Job Postings for Employers and Recruiters
5. Just in Time for the Holiday Rush, Braintree Stylist Bruce Fisher Offers Holiday Style & Beauty Tips
6. Physical therapy offers evidence-based solution to musculoskeletal pain
7. True Data Offers New Special Leasing Rates on Dialogic, Samsung, & Vertical Communications Products
8. How to Change Someone You Love Seminar Offers Help to Those Who Feel Powerless in the Face of Addiction
9. Partnership for Prevention Offers Health Reform Recommendations to Congress
10. Reid Supply Offers Free Educational Technical Resource Guides
11. All Nursing Schools Offers Continuing Education Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to ... as drinking more water or limiting their exposure to the sun, according to a ... beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ...
(Date:12/6/2016)... ... December 06, 2016 , ... An inventor, from Talladega, Ala., thought there ... she invented the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support ... to traditional slings. As a result, it helps to reduce discomfort and shifting. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health insights for population health management, announces today a strategic relationship with ... CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures (CQM) ...
(Date:12/6/2016)... ... December 06, 2016 , ... It ... Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to check out ... resource. The expo’s beneficiary this year was Crossroads, a fully-accredited gender-responsive treatment ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new ... after launch. Almost 200 backers pledged more than $25,000 on Kickstarter ... , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology: